Your session is about to expire
← Back to Search
Nanochip Technology for B-Cell Lymphoma
N/A
Recruiting
Led By Beth Christian, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histologically confirmed treatment naive DLBCL. Subtypes including high grade B-cell lymphoma, not otherwise specified (NOS) and de-novo DLBCL including germinal center B-cell type (GCB) and non-GCB subtypes.
Receiving treatment with curative intent.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group
Summary
This trial uses a special tiny chip to monitor treatment response and detect relapse in patients with diffuse large B-cell lymphoma by checking their blood for specific genetic markers. Rituximab has been a key component in treating diffuse large B-cell lymphoma.
Who is the study for?
This trial is for people with a specific blood cancer called diffuse large B-cell lymphoma (DLBCL) who haven't been treated before. Participants must plan to get all their care at Ohio State University, aim for a cure with treatment, and go through 6 cycles of chemotherapy. They also need to be able to give consent.
What is being tested?
The study is testing nanochip technology (ILN biochip) to see how well it can monitor the effectiveness of treatments in real-time and detect any return of the disease in patients with DLBCL. Researchers are looking for genetic markers that could predict treatment outcomes.
What are the potential side effects?
Since this trial focuses on monitoring technology rather than direct treatment, there may not be side effects related directly to the ILN biochip itself. However, standard chemotherapy side effects apply.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a specific type of untreated lymphoma.
Select...
I am undergoing treatment aimed at curing my condition.
Select...
I am scheduled for 6 chemotherapy sessions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Early detection of relapse
Treatment response
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (ILN biochip testing)Experimental Treatment1 Intervention
Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Non-Hodgkin's Lymphoma (NHL) include chemotherapy, immunotherapy, and targeted therapy. Chemotherapy works by killing rapidly dividing cells, including cancer cells.
Immunotherapy, such as monoclonal antibodies (e.g., rituximab), targets specific proteins on the surface of lymphoma cells, marking them for destruction by the immune system. Targeted therapies, like Bruton tyrosine kinase (BTK) inhibitors, interfere with specific molecules involved in cancer cell growth and survival.
Understanding these mechanisms is crucial for NHL patients because it helps in tailoring treatments to individual genetic profiles, improving efficacy, and minimizing side effects. Additionally, detecting genetic markers for treatment response and relapse, as studied in the ILN Biochip trial, can lead to more personalized and timely adjustments in therapy, potentially improving outcomes.
Find a Location
Who is running the clinical trial?
Ohio State University Comprehensive Cancer CenterLead Sponsor
340 Previous Clinical Trials
293,025 Total Patients Enrolled
Beth Christian, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center
3 Previous Clinical Trials
83 Total Patients Enrolled
Narendranath Epperla, MDPrincipal Investigator - Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
1 Previous Clinical Trials